𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chlordiazepoxide loses its anxiolytic action with long-term treatment

✍ Scribed by Sandra V. Vellucci; Sandra E. File

Book ID
104770650
Publisher
Springer
Year
1979
Tongue
English
Weight
480 KB
Volume
62
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis

The biochemical and behavioural effects of acute, 5, 15 and 25 days treatment with chlordiazepoxide (CDP, 5 mg/kg) were examined in the rat. After 5 days of drug treatment, 5-hydroxytryptamine (5HT) levels in the midbrain, hypothalamus and cortex were significantly higher than those of the corresponding controls, and the level of 5-hydroxyindoleacetic acid (5HIAA) was significantly lower, indicating reduced turnover. After 15 days of drug treatment, 5HIAA levels were significantly elevated, compared with the controls, possibly indicating that CDP was blocking the transport of 5HIAA from the brain. This effect appears to be independent of the reduced turnover. After 25 days of drug treatment there were no significant differences compared with the controls. There were no marked changes in noradrenaline and dopamine in any of the areas investigated. It appears that the reduction in 5HT turnover is linked to the anxiolytic effects of CDP; the latter were found after 5 days of drug treatment, but not after 15 or 25 days, using the social interaction test of anxiety.

📜 SIMILAR VOLUMES

Crohn's disease and color Doppler sonogr
Crohn's disease and color Doppler sonography: Response to treatment and its relationship with long-term prognosis
✍ Tomás Ripollés; María J. Martínez; María M. Barrachina 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## Purpose To evaluate the ability of sonography to detect changes in patients undergoing treatment for Crohn's disease and whether these findings are related to the patient's long‐term outcome. ## Methods Twenty‐eight patients with Crohn's disease were examined prospectively using g

Plasma level monitoring of mitotane (o,p
Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of cushing's disease with low doses
✍ R. Benecke; E. Keller; B. Vetter; R. A. Zeeuw 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 345 KB

Mitotane (o,p'-DDD) can be used for the treatment of various adrenocortical diseases such as Cushing's syndrome, but the usual doses of 6-8 g per day are often associated with severe adverse effects. This paper reports the results of much lower doses of o,p'-DDD (0.5-2 g per day) in two patients wit

Atorvastatin has cardiac safety at inten
Atorvastatin has cardiac safety at intensive cholesterol-reducing protocols for long term, yet its cancer-treatment doses with chemotherapy may cause cardiomyopathy even under coenzyme-Q10 protection
✍ Metin Caner; Bingur Sonmez; Ozlem Kurnaz; Caner Aldemir; Seda Salar; Tuncay Altu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 788 KB

## Abstract Statins provide strong clinical benefits via reducing stroke deaths, and they are also considered for tumor reduction and chemo‐sensitization. High dose atorvastatin in adults (80 mg daily, approx. 1 mg/kg) is proven to afford greater protection against cardiac deaths than does a standa